Krishnan
@krishnaniyer199
Followers
37
Following
1K
Media
0
Statuses
154
Joined January 2010
Our most recent work provides strong rationale for combination of KRAS inhibitors & anti-CTLA4 in clinical trials. KRASi synergize with anti-CTLA4 to prevent resistance by epigenetic reprogramming of Tregs & TLS recruitment. @Aiims1742 @KalluriLab.
biorxiv.org
Lack of sustained response to oncogenic Kras (Kras*) inhibition in preclinical models and patients with pancreatic ductal adenocarcinoma (PDAC) emphasizes the need to identify impactful synergistic...
2
2
7
RT @rkalluriMDPhD: 📣Coming Soon: Extracellular Vesicles and Exosomes Biology Core Facility (EVcore). A first of its kind facility to suppor….
0
20
0
@timheff5 Find companion manuscript in pre-print with iExosomes targeting KRAS sensitising PDAC to anti-CTLA4 therapy. Detailed characterization of iExo in non-human primates & phase1 trial data with direct clinical relevance. @KalluriLab.
medrxiv.org
Oncogenic KRAS drives initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with KrasG12D specific siRNA (iExoKrasG12D) reveal impressive...
0
0
0
RT @Val_LeBleu: KRASG12D-Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Ch….
medrxiv.org
Oncogenic KRAS drives initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with KrasG12D specific siRNA (iExoKrasG12D) reveal impressive...
0
6
0
ScATAC/RNA seq and demonstrate downregulation of AP1 TFs on IL10 & IL35 promoter/enhancer regions in Tregs of KRASi+aCTLA4 treated PDAC. TLS in combination therapy show expansion of germinal center, IFN stimulated Bcells and plasma cells. Great team effort with @Bingruilii.
0
0
1
RT @KalluriLab: Many thanks to @DeNardoLabWUSM for their spotlight article on our cDC1 vaccine. 👉 ICYMI: our work….
0
3
0
RT @SGoswamiMDPhD: I am happy to share the latest paper from Goswami_Lab in Nature Immunology. We showed the integration of metabolic & epi….
0
31
0
RT @hollynzhou: A huge thank you to my mentor Dr.Kalluri @rkalluriMDPhD and Dr.LeBleu @Val_LeBleu. I cannot make it without the support of….
0
2
0
Excellent news article from ACIR highlighting our cDC1 work.
acir.org
Pancreatic ductal adenocarcinoma (PDAC) remains refractory to immunotherapy due to a compromised tumor immune microenvironment (TIME) with dysfunctional T cells, suppressive myeloid and regulatory T...
0
0
0
RT @KalluriLab: In @ImmunityCP, Raghu Kalluri discusses the role of extracellular vesicles (EVs) in immune response and immunity. Might EVs….
0
7
0
RT @RonDePinho: Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. @KalluriLab @MDAndersonNews 👏👏👏 https:/….
sciencemagazinedigital.org
INTRODUCTION: Sites of chronic tissue injury and inflammation demonstrate an increased propensity to develop cancers.
0
4
0
RT @Aiims1742: New @ScienceMagazine publication from @KalluriLab @MDAndersonNews .Type I conventional dendritic cells facilitate immunother….
0
35
0
cDC1 vaccine facilitates curative immunotherapy in Panvreatic cancer. Our work from @KalluriLab @rkalluriMDPhD published in @ScienceMagazine today. Thanks to a great collaboration with @swatowic lab and Allison on our work.
science.org
Inflammation and tissue damage associated with pancreatitis can precede or occur concurrently with pancreatic ductal adenocarcinoma (PDAC). We demonstrate that in PDAC coupled with pancreatitis...
4
0
7
RT @KalluriLab: "Immunotherapies alone have made little impact against pancreatic cancer, but new research suggests combining them with KRA….
nature.com
Immunotherapies alone have made little impact against pancreatic cancer, but new research suggests combining them with KRAS-G12D inhibition may hold the key to durable responses.
0
2
0
RT @MDAndersonNews: From a combination therapy for KRAS-mutated pancreatic cancer to potential targets for improving stomach cancer treatme….
0
3
0
RT @OncologyTimes: Researchers at @MDAndersonNews found a role for KRAS mutations in pancreatic cancer and created a novel therapeutic appr….
0
2
0
RT @lustgartenfdn: Lustgarten-funded science making headlines! "Leveraging the immune system by combining KRAS inhibitors w/ immunotherapy….
mdanderson.org
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeu...
0
2
0
RT @Aiims1742: Main credit goes to the hard work of @krishnaniyer199 & @mcandrews_kate from @KalluriLab. You can find them both at #AACRPan….
0
2
0